All Studies (9)
Diabetes mellitus is an important health problem in both dogs and people. Type 1 diabetes (T1D) in people is caused by an attack of the body’s own immune system on cells in the pancreas. Diabetes in dogs is thought to be similar in some ways to T1D in people, but there is still much more to learn about the causes of diabetes in dogs as well as better ways to prevent and treat the disease. The purpose of this study is to learn more about metabolism and immune function in diabetic dogs.Read More
Your dog has been recently diagnosed with canine diabetes
- A diagnosis of Canine Diabetes within the last 4 weeks
- Adult age (Older than 1 year)
- Body weight greater than 6.5 lbs (3 kg)
Your dog has other endocrine related disease or is a non-spayed female
- Non-spayed females
- Current diagnosis of destrus diabetes or hyperadrenocorticism(Cushing's Disease)
- Weight under 6.5 pounds
DCM in Dobermans
Dilated Cardiomyopathy (DCM) is a disease of heart muscle that results in a decreased ability of the heart to pump blood. The prognosis for DCM is often poor, with a less than 50% survival rate one year after clinical signs develop, unless a reversible underlying cause is identified. There is no available cure for Dilated Cardiomyopathy, current techniques focus on extending survival time as long as possible. However the focus of this clinical trial is to evaluate a potential curative treatment for cardiomyopathy in the Doberman Pinscher.Read More
Your dog has been diagnosed with dilated cardiomyopathy
- A diagnosis of DCM and previous evidence of congestive heart failure which has been controlled with medical management.
- A circulating neutralizing antibody titer to the virus vector of less than 1:20
- Owner agreement to authorize participation with informed consent and collection of the heart following euthanasia or death from any cause.
Your dog has no other heart conditions
- Clear of extra-cardiac disease, congenital heart disease or primary mitral valvular disease
Lymphoma is one of the most commonly encountered cancers in the dog. The incidence of canine lymphoma has steadily increased with approximately 84 per 10,000 dogs diagnosed each year. This randomized, double-masked, placebo-controlled, GCP pivotal field study is evaluating the effectiveness and safety of verdinexor for the treatment of naïve or first relapse stages II, III and IV lymphoma in client owned dogs. Diagnosis of lymphoma must be confirmed by cytology or biopsy for the dog to be eligible for this study. Dogs will be randomized to receive the investigational veterinary product or a placebo treatment (tablets) to be administered with food twice weekly at least 72 hours apart for 8 weeks. After receiving treatment in-hospital on Day 0, the dog will be required to return to the study site on Days 7, 14, 28, 42, and 56 for follow up evaluation visits. Owners will be required to report and record abnormal daily observations and dosing using a phone app at home throughout the study.Read More
Your dog has naïve or first relapse lymphoma
Naïve: dog who has not received any treatment for lymphoma.
First relapse: dog has failed a single round of any chemotherapy completed at least 14-days prior to study entry and has recovered from any acute toxicity from prior chemotherapy or is on prednisone and has exhibited progressive disease.
Your dog is over 1 year old and weighs more than 9kgs (~20lbs)
Your dog is ≥ 1 year, weighs ≥ 9 kg and has a life expectancy of at least 28 days.
Your dog has a diagnosis of lymphoma
Your dog has a diagnosis of lymphoma by cytology (fine needle aspirate of the lymph node) and/or histopathology (biopsy)
Investigating a New Treatment for Hemangiosarcoma
Hemangiosarcoma is the most common splenic cancer diagnosed in dogs. The standard of care treatment is splenectomy (surgery) followed by doxorubicin chemotherapy, but long-term survival remains poor. We are continuously looking for additional well-tolerated treatments that may prolong survival for dogs with this disease.Read More
Your dog has had a splenic Hemangiosarcoma
Your dog must not be on any supplements such as Yunnan baiyao or I'm Yunity/turkey tail mushroom.
Your dog must not have evidence of metastasis (spread of disease).
Dietary Trial for Cats with IBD or GI Lymphoma
The clinical signs in some cats with chronic enteropathy (chronic vomiting and/or diarrhea) can be reversed with dietary management using a specially formulated diet. It is not clear why some cats respond to diet, or what the optimal composition of the diet for cats with chronic enteropathy should be. We want to know if diets containing proteins that are selected to minimize immune responses and fortified in Vitamin B12 and natural anti-inflammatory agents (prebiotics and curcumin) are better than conventional diets for cats with chronic enteropathy.Read More
Any Cat with signs of chronic GI disease
Your cat must have signs of chronic GI disease (of more than 3 weeks duration), have had non-GI causes of vomiting and/or diarrhea ruled out, and must be amenable to blood sampling at the times required by the study.
Your cat must currently be symptomatic.
Sequencing the Genes of Dogs with Acute Myeloid Leukemia
Acute myeloid leukemia is a cancer of the blood. Although uncommon, it is a highly aggressive form of cancer and often kills dogs quickly, particularly because we don’t have many drugs that we can use to treat the leukemia. Great strides have been made in humans with acute myeloid leukemia, which is similar to the disease we see in dogs. However, unlike humans, we know very little about the genetic mutations that underlie acute myeloid leukemia in dogs, which is the goal of this studyRead More
Selective Inhibition of Nuclear Export (SINE) and Canine Osteosarcoma
Osteosarcoma is a common cancer diagnosed in dogs, particularly in large breed dogs. While several chemotherapy protocols have been shown to provide modest management of the onset of metastasis (spread of cancer), we are continuously looking for additional treatments that may extend survival time. Carboplatin is a widely accepted chemotherapy agent used in treatment of osteosarcoma. The results of this study will allow us to determine if dogs can successfully tolerate carboplatin and a new drug called Laverdia-CA1 (verdinexor) in a combination protocol.Read More
Your dog has been seen by CUHA
Patients must have been previously treated at Cornell University Hospital for Animals
Your dog has had limb amputation due to osteosarcoma
Patients must had been diagnosed with osteosarcoma and had limb amputation at Cornell University Hospital for Animals previously.
You dog has NOT received any chemotherapy
Patients must not have received chemotherapy treatment previously
Performance of a New Point-of-care Rapid Test to Diagnose Pulmonary Coccidioidomycosis
Diagnosis of coccidioidomycosis in dogs is challenging due to the fact that the symptoms are not specific for this disease. Coccidioidomycosis can be diagnosed via a biopsy however the most common method is testing for antibodies to the fungus. These tests are often sent to third party labs delaying confirmation of the disease. This study looks to evaluate a potential point of care rapid test which would be able to provide a positive or negative result indicating the presence or absence of antibodies, respectively, within 30-60 minutes. The diagnosis of pulmonary coccidioidomycosis can be difficult because clinical signs overlap with many other respiratory tract disorders and dogs can have positive Valley Fever antibody titers without active clinical infection. Acute phase proteins are useful biomarkers for many other disorders and our hope is to determine whether they can facilitate making a diagnosis of pulmonary coccidioidomycosis in dogs. For additional details or questions please contact Dr. Jaffey (firstname.lastname@example.org).Read More
Your dog has a a confirmed or suspected novel diagnosis of pulmonary coccidioidomycosis
Your dog has a a confirmed or suspected novel diagnosis of pulmonary coccidioidomycosis
Your dog has at least 1 respiratory sign
Your dog has one of the following respiratory signs:
Your dog has not received an anti-fungal treatment more than 7 days before enrollment
Dog must not have received an anti-fungal treatment for more than 7 days before enrollment
Efficacy of twice-daily nebulized budesonide for the treatment of canine chronic bronchitis: a pilot study
Canine chronic bronchitis is an inflammatory disease characterized by a cough for > 2 months without another identifiable cause. Dogs with chronic bronchitis have persistent airway neutrophilic inflammation. The foundation of long-term therapy is corticosteroids. Oral prednisone is commonly used but has a litany of possible adverse effects. Inhaled steroids is an alternative to avoid the adverse effects of prednisone but the only available option is fluticasone. This medication is expensive and has variable efficacy. Inhaled budesonide is a medication used in humans to treat a similar airway disorder and is a fraction of the cost. This study aims to investigate the benefit of inhaled budesonide on respiratory tract symptoms in dogs with chronic bronchitis.Read More
Your dog has a chronic cough for longer than 2 months
Dogs with a history of cough exceeding two months may be eligible for the study.
Your dog has thoracic radiographs performed in the past 3 months
Thoracic radiographs will be used by principal investigator to determine eligibility.
Your dog does NOT have an alternative cause for chronic cough
Dogs with alternative caused for chronic cough such as tracheal collapse, heart disease, cancer, Valley Fever, etc are not eligible for this study.
Your dog has not received previous treatment with corticosteroids
Dogs who have received previously received corticosteroids for treatment of chronic cough are not eligible for this study.